Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7861568 | 0.98 | HSD11B1 (0.32) | HSD11B1ALOX5APEPHX2CA12CA2 | |
| SCHEMBL124615 | 0.76 | GRIN2D (0.37) | ALOX5AP | |
| Hydrochloric Acid SCHEMBL7861667 | 0.74 | ALDH1A1 (0.49) | HSD11B1 | |
| SCHEMBL16229102 | 0.74 | HSD11B1 (0.36) | HSD11B1ALOX5APEPHX2CA12CA2 | |
| SCHEMBL6441140 | 0.72 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL3926739 | 0.70 | HSD11B1 (0.49) | HSD11B1 | |
| SCHEMBL7863315 | 0.68 | ALOX5AP (0.31) | ALOX5AP | |
| SCHEMBL11879634 | 0.67 | GRIN2D (0.42) | — | |
| SCHEMBL7235205 | 0.67 | HSD11B1 (0.38) | HSD11B1 | |
| SCHEMBL10850143 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888285-B1 | NOVEL BRIDGED CYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2001-12-12 | — | — | EP | claimed |
| US-6020370-A | ANTIEPILEPIC AGENT, BRAIN DISORDERS, NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS, ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-02-01 | — | — | US | claimed |
| EP-0888285-A1 | NOVEL BRIDGED CYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997033859-A1 | NOVEL BRIDGED CYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-09-18 | — | — | WO | claimed |
| EP-0888285-B1 | NOVEL BRIDGED CYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2001-12-12 | — | — | EP | disclosed |
| US-6020370-A | ANTIEPILEPIC AGENT, BRAIN DISORDERS, NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS, ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0888285-A1 | NOVEL BRIDGED CYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997033859-A1 | NOVEL BRIDGED CYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-09-18 | — | — | WO | disclosed |